A3 - Beyond COVID – Catalysing vaccine technology and drug delivery
Organised in collaboration with FIP’s Hospital Pharmacy Section
Chair(s)
Introduction
The pace of development of COVID-19 vaccines has been nothing short of a modern miracle. There is, perhaps, no bigger story than the transition of mRNA technologies from relatively small-scale experimental approaches to clinical implementation on a grand scale. This experience has stimulated increased interest in the development of other technologies that have followed a similar development history to mRNA. This session will explore some of these technologies in the management of conditions beyond COVID and consider the implications for health care.
Programme
| 14:00 – 14:10 | Introduction by the chair | |
| 14:10 – 14:35 |
|
Overview of mRNA COVID-19 vaccine, cell-based gene therapy, and future oncology therapeutics development Dr Josep Maria Guiu Segura, Consortium of Health and Social Care of Catalonia, Spain |
| 14:35 – 15:00 |
|
Brazilian advances on regulation of vaccine and medicines |
| 15:00 – 15:20 | Panel discussion and Q&A | |
| 15:20 – 15:30 |
|
Conclusion by the chair |
Learning Objectives
- To describe mRNA vaccine technology
- To describe emerging technologies such as cell-based therapy
- To describe therapeutic applications of mRNA and cell-based therapy beyond COVID-19
- To discuss the potential implications of these technologies for health care
